Ilya Pharma awarded European patent covering engineered Lactobacillus reuteri strains for use in cutaneous wound therapy
Patent covers treatment of cutaneous human and animal wounds using transformed lactic acid bacteria
News
Ilya Pharma approved for funding by the European Innovation Council Equity Fund for high-impact innovation
Bloomberg reports: EU will become shareholder in startups for the first time.
Ilya Pharma announces positive results from Phase I trial of lead candidate ILP100 and rapid move to Phase II
Success also de-risks the use of ILP-drug candidates in other medical indications, including the company’s inflammatory bowel disease program.
Latest clinical developments and next raise to be presented at EIC Investor Day 2.0 17-18 December
FDA open to new endpoints for patients with difficult wounds
FDA opened for 5 new endpoints in Nov 2020 (vs. only 1 until then) following thorough work by FDA’s Inter-center Wound Healing Work group and industry Wound Experts/FDA Clinical Endpoints Project.
Meet Ingemar Kihlstörm - facilitating the next stage of growth
Financing innovations in pharmaceutical development – facilitating the next stage of growth